| |
EuroHIV-HepMtg2024: Multivariable Models to Identify Predictors of Virologic Response to Fostemsavir in BRIGHTE
|
| |
| |
European Meeting on HIV & Hepatitis; May 22-24, 2024; Barcelona, Spain
Gartland M1, Wang X1, Liao Q1, Li B2, Du F2, Krystal M3, Clark A4, Tenorio A3,
Castillo-Mancilla J1
1ViiV Healthcare, Durham, USA, 2GSK, Collegeville, USA, 3ViiV Healthcare, Branford, USA, 4ViiV Healthcare, Brentford, UK
ABSTRACT
Results: Factors associated with virologic response <40 c/mL in the RC at Week 96 were BL HIV VL, number of fully active and available ARVs in the initial OBT, and overall susceptibility score to newly used ARVs in the initial OBT. Additional factors-BL gp160 substitutions S375H/I/M/N/Y, M426L, or M434K and use of DTG-were identified in RC participants through Week 192. In NRC participants, factors associated with HIV VL <40 c/mL were BL VL, BL CD4+ T-cell count, number of fully active and available ARVs in the initial OBT, and susceptibility score to the OBT. Presence of ≥3 BL factors (CD4+ T-cell count <20 cells/mm³, HIV VL ≥100,000 c/mL, ART duration >20 years, or presence of gp160 substitutions) had a low predictive value for PDVF in RC participants through Weeks 96 and 192 (PPV 35% and 39%, respectively).
Conclusions: While multivariable analyses identified several factors that were predictive of virologic response at Weeks 96 and 192, the factors explored in the BL factor analysis were not highly predictive of PDVF at these later time points. These results provide additional data on the long-term efficacy of FTR as a treatment option for HTE people with multidrug-resistant HIV-1 with a wide range of BL disease characteristics.
|
|
| |
| |
|
|
|
